<DOC>
	<DOC>NCT02037776</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of Rikkunshito compared to placebo in Japanese subjects with Functional Dyspepsia.</brief_summary>
	<brief_title>The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia</brief_title>
	<detailed_description />
	<mesh_term>Dyspepsia</mesh_term>
	<mesh_term>Gastritis</mesh_term>
	<criteria>Patients diagnosed with FD according to the ROME III criteria i) Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to obtaining informed consent ii) Have not received upper endoscopy within the last 6 months prior to enrollment and do not have evidence of structural/organic disease iii) Must have one or more of the following symptoms: 1. Bothersome postprandial fullness 2. Early satiation 3. Epigastric pain 4. Epigastric burning At least one of the FDrelated symptoms on the Global Overall Symptom (GOS) scale (bothersome postprandial fullness, early satiation, epigastric pain, epigastric burning) is ≥4, whereas heartburn is ≤3. Total score of depressionrelated symptoms on Hospital Anxiety and Depression Score (HAD) is ≤10. Type of visit: Outpatient Provides voluntary informed consent after receiving adequate explanation and demonstrates thorough understanding of the nature of the study. Confirmed ulcer (excluding scars) or malignant tumor in the upper GI Suspected organic lesions in the hepatobiliarypancreatic regions such as cholelithiasis, hepatitis, pancreatitis History of upper GI resection Serious complications (liver, kidney, heart, or blood disease or metabolic disease) Less than a year since testing positive for H. pylori or have undergone a successful eradication therapy Use of prohibited medications Neuropsychiatric disorders Use of or planned use of any investigational drugs Unable to take drugs orally History of allergic reactions to Kampo medicines Pregnant or lactating women or those who are planning to conceive during the study period Deemed ineligible by principal investigator or subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Rikkunshito</keyword>
	<keyword>Double blind</keyword>
	<keyword>Functional dyspepsia (FD)</keyword>
</DOC>